Aspira Womens HealthAWHL +3.84%36 Net Margin % is 34.37% as of Mar. 2026. GuruFocus rates AWHL with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Aspira Womens Health ranks worse than 81.37% on this metric.
The historical rank and industry rank for Aspira Womens Health's Net Margin % or its related term are showing as below:
AWHL'
s Net Margin % Range Over the Past 10 Years
Min: -566.54 Med: -350.75 Max: -115.13
Current: -115.13
AWHL's Net Margin % is ranked worse than 81.37% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs AWHL: -115.13
Aspira Womens Health (OTCPK:AWHL) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Aspira Womens Health Net Margin % Related Terms
Aspira Womens Health Net Margin % Historical Data
* Premium members only.
The historical data trend for Aspira Womens Health's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Aspira Womens Health's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Net Margin % distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (AWHL) has a Net Margin % of 34.37% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Aspira Womens Health and its competitors. According to the industry distribution chart, Aspira Womens Health ranks #166 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 81.4%.
Is Aspira Womens Health's Net Margin % too high?
Aspira Womens Health's current Net Margin % is 34.37%. Based on the distribution chart, Aspira Womens Health ranks #166 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Aspira Womens Health has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's Net Margin % compare to BIOQ and MBAI?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Womens Health ranks #166 out of 204 companies for Net Margin %. This places Aspira Womens Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Aspira Womens Health and its competitors. Aspira Womens Health's current Net Margin % is 34.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.43 — trading 52.1% above its estimated fair value. The current Net Margin % is 34.37%. Aspira Womens Health's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current Net Margin % is 34.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Womens Health (AWHL) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued.
The current stock price of $0.43 is trading 52.1% above its estimated GF Value™ of $0.28.
GuruFocus considers Aspira Womens Health to be Significantly Overvalued.
Key valuation signals for AWHL:
Net Margin %: 34.37%
GF Value™: $0.28 vs. price of $0.43 (52.1% above fair value)
No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
36GF Score
Get the complete analysis for AWHL
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AWHL has been successfully added to your 
